Current Report Filing (8-k)
March 30 2020 - 01:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 30,
2020
BIOXYTRAN, INC.
(Exact Name if Business Issuer as specified in its Charter)
|
Nevada |
|
26-2797630 |
(State
or other Jurisdiction
of Incorporation) |
|
(IRS
Employer
Identification Number) |
233 Needham Street, Suite 300
Newton MA, 02464
(Address of principal executive offices, including zip code)
(617) 494-1199
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR
240.1 4a- 12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 1 4d-2(b) under the Exchange Act
(17 CFR 240.1 4d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 1 3e-4(c) under the Exchange Act
(17 CFR 240.1 3e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
| |
|
|
|
|
Item 8.01. Other Events.
On March 30, 2020, Bioxytran released a presentation to be
integrated on the company web-site in reference to the Company’s
COVID-19 approach. The presentation is attached hereto as Exhibit
99-1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
Bioxytran,
Inc. |
| |
|
|
| |
By: |
/s/
David Platt |
| |
|
Name: |
Dr.
David Platt |
| |
|
Title: |
President
and Chief Executive Officer |
Dated: March 30, 2020
2
